Navigation Links
Installation of Next Generation Proton Therapy System Progressing Rapidly
Date:10/26/2010

LITTLETON, Mass., Oct. 26 /PRNewswire/ -- Still River Systems' groundbreaking proton therapy system is entering the final phase of installation at the Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis, MO, a National Cancer Institute (NCI) Comprehensive Cancer Center. The precision of proton therapy makes it an important treatment option for patients with cancer, as it spares the healthy tissue and results in far fewer short- and long-term treatment complications. This unique device houses a revolutionary proton source based on the world's first superconducting synchrocyclotron and provides a significant reduction in the size, cost and complexity of developing and operating a proton therapy center.

This next generation proton therapy system is installed in three simple phases, in a radiation therapy room comparable in surface to that of conventional radiotherapy systems. Phase 1 consists of rigging and mounting the accelerator gantry, which holds and positions the proton source with sub-millimeter accuracy.  Phase 2 includes assembling and installing the clinical environment which comprises the 6D robotic couch, the high-accuracy treatment gantry and its applicators, the 2D/3D imaging and positioning systems and the clinical software interfaces.  The third and final phase consists of the installation of the accelerator module.   "The execution of phases 1 and 2 of the first installation went very smoothly and we are targeting 2 months to complete them in future installations," explains Bill Alvord, Vice President of Operations.

The production accelerator is now undergoing clinical commissioning, and all clinical parameters have exceeded performance expectations.  "The innovative design of our proton therapy system is simple and modular thus ensuring a lean and fast production line followed by a quick and efficient system installation," states CEO Joseph Jachinowski. "With our first system produced and its installation nearing completion, we are now reaping the benefits of its unique design by finalizing a complete process that can be replicated to meet the growing proton therapy demand."

Still River Systems will be exhibiting at the 52nd Annual Meeting of the American Society for Radiation Oncology in San Diego California on October 31st through November 3rd.  

ABOUT STILL RIVER SYSTEMS

Still River Systems, Inc., based in Littleton, Massachusetts, is dedicated to providing physicians, and their patients, access to high quality, cost-effective proton therapy solutions. Still River Systems is developing the Monarch250, an affordable, precise and compact proton therapy system for cancer treatment.

The Monarch250 has not been cleared by the US Food and Drug Administration for distribution or clinical use. For more information on Still River Systems and the Monarch250 Proton Therapy System, please call 978-540-1500 or visit www.stillriversystems.com


'/>"/>
SOURCE Still River Systems
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. New TROY SecureRx Prescription Printer Marks 50th Hospital Installation Milestone
2. Heska Announces First Installation of New Blood Gas & Electrolyte Analyzer
3. Health Robotics Surpasses 100 Installations Milestone and Acquires Two I.V. Room of the Future Partner Companies
4. Low Installation Rates in Retail Pharmacies Across Europe Increase the Growth Potential of the Pharmacy Automation Systems Market, Finds Frost & Sullivan
5. Althea Technologies Announces the Installation of a High-Speed Prefilled Syringe Line
6. Abbott and AstraZeneca Announce Selection of Next-Generation Fenofibrate ABT-335 and CRESTOR(R) Fixed-Dose Combination
7. Kosans Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial
8. Beaumont Patients 1st to get Next Generation of Radiation Treatment
9. Boston Scientifics Next-Generation Stent Shows Improved Clinical Outcomes in Complex Lesions
10. BiPar Announces Preclinical Data Demonstrating Anti-Tumor Activity With BSI-401, Its Second-Generation PARP Inhibitor
11. Acologix Presents Preclinical Data on Cartilage Regeneration by AC-100 at the OARSI 2007 World Congress on Osteoarthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 23, 2016  Astellas today announced the establishment of Astellas Farma Colombia (AFC), a new affiliate with operations headquartered ... Latin America . ... ... ... ...
(Date:6/23/2016)... 2016  Guerbet announced today that it has been ... Award . One of 12 suppliers to ... its support of Premier members through exceptional local customer ... commitment to lower costs. ... our outstanding customer service from Premier," says Massimo ...
(Date:6/23/2016)... Research and Markets has announced ... Analysis (United States, China, Japan, Brazil, United Kingdom, Germany, ... offering. Surgical Procedure ... planners, provides surgical procedure volume data in a geographic ... in-depth analysis of growth drivers and inhibitors, including world ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... 2016 , ... PawPaws brand pet supplements owned by Whole Health ... the health of felines. The formula is all-natural and is made from Chinese herbs ... Cat Kidney Support Supplement Soft Chews are Astragalus Root Extract and Rehmannia ...
(Date:6/25/2016)... ... 25, 2016 , ... The temporary closing of Bruton Memorial Library on June 21 due to ... a new, often overlooked aspect of head lice: the parasite’s ability to live away from ... common occurrence, but a necessary one in the event that lice have simply gotten out ...
(Date:6/25/2016)... ... ... Friday, June 10, Van Mitchell, Secretary of the Maryland Department of Health and Mental ... exemplary accomplishments in worksite health promotion. , The Wellness at Work Awards took place ... BWI Marriott in Linthicum Heights. iHire was one of 42 businesses to receive an ...
(Date:6/24/2016)... ... ... crisis. Her son James, eight, was out of control. Prone to extreme mood shifts and ... him, he couldn’t control his emotions,” remembers Marcy. “If there was a knife on ... say he was going to kill them. If we were driving on the freeway, ...
(Date:6/24/2016)... ... ... BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a ... an hour by 2020 and then adjusting it yearly to increase at the same rate ... assure the wage floor does not erode again, and make future increases more predictable. , ...
Breaking Medicine News(10 mins):